Metrics as of 10/17/2026, 09:36 AM (Berlin time), refresh in progress.
Crescent Biopharma Stock
Crescent Biopharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Joshua T. Brumm
- Employees
- 44
- Market cap
- $440 M
- IPO
- 10/01/2014
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's…
Crescent Biopharma stock: price history
1D
-5.1%
1W
-20.6%
1M
-31.1%
6M
-44.4%
YTD
-0.2%
1Y
-4.1%
2Y
-24.5%
5Y
-94.0%
10Y
-98.0%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~165% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Crescent Biopharma stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Crescent Biopharma is a biotechnology company focused on the research and development of novel cancer therapies. Its portfolio comprises various drug candidates including the proprietary bispecific antibody CR-001, which simultaneously addresses PD-1 and VEGF signaling pathways to treat solid tumors. Additionally, drug candidates CR-002 and CR-003 are in development. The company maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to jointly advance innovative oncology therapeutics and combination approaches.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Crescent Biopharma
Analyst assessment of Crescent Biopharma
PRICE TARGET LOW
US$36.00
CONSENSUS
US$36.00
MEDIAN
US$36.00
PRICE TARGET HIGH
US$36.00
0
STRONG BUY
10
BUY
4
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 06/10/2026
Crescent Biopharma stock metrics
P/E
-1.56
P/B
2.21
EV/EBITDA
-1.66
RETURN ON EQUITY
-13.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
49.8%
FLOAT SHARES
18,511,243
AVG. DAILY VOLUME (30D)
471,226
Insider transactions (SEC)
Lynch Ryan
McNeill Jonathan
McNeill Jonathan
Brumm Joshua T
Brumm Joshua T
Attention
Price since yesterday: -5.1%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Crescent Biopharma stock
What does Crescent Biopharma do?
Crescent Biopharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Joshua T. Brumm, the company employs around 44 people.
The IPO was on 10/01/2014; the stock trades on NASDAQ under the ticker CBIO.
What do analysts say about Crescent Biopharma stock?
14 analysts rate the stock, the consensus is Buy (as of 06/10/2026).
The average price target is US$36.00, ranging from US$36.00 to US$36.00, with a median of US$36.00.
This is an external assessment, not a statement by Market Jury.
When does Crescent Biopharma report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 165% stronger than usual.
Does Crescent Biopharma pay a dividend?
Yes. The last dividend was US$0.24 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Crescent Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Crescent Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Crescent Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.